睿知中国疾病研究地图
候选清单0

即将招募胃癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

ClinicalTrials.gov 上登记的一项胃癌开放试验,由郑州大学第一附属医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方郑州大学第一附属医院First Affiliated Hospital of Zhengzhou University郑州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06492317,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Confirmed locally advanced or distant metastasis gastric or gastroesophageal junction adenocarcinoma that is inoperable by pathological examination;

    入选标准第 2 条

  3. Cardiac function: New York Heart Association (NYHA) classification<Grade 3; Left ventricular ejection fraction≥50%;

    入选标准第 14 条

    NYHA grade 2 or above heart failure;

    排除标准第 3 条

  4. There is no prior systematic treatment, or the patient has received neoadjuvant/adjuvant chemotherapy, and the disease progresses or relapses more than 6 months after the treatment;

    入选标准第 5 条

    Received systematic treatment with Chinese patent medicine or immunomodulatory drugs (including thymosin, interferon, interleukin, except for local use for ascites control) before the first administration within 2 weeks;

    排除标准第 11 条

  5. Eastern Cooperative Oncology Group (ECOG)performance status of 0-1;

    入选标准第 6 条

  6. Bone marrow function: Hemoglobin count (HGB)≥80g/L;

    入选标准第 8 条

    Neutrophil count (NE)≥1.5×109/L;

    入选标准第 9 条

    White blood cell count (WBC)≥3.5×109/L;

    入选标准第 10 条

    Platelet count (PLT)≥100×109/L;

    入选标准第 11 条

    Liver function: i. Serum total bilirubin (TBIL)≤1.5×ULN; ii. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP)≤3×ULN, patients with liver metastasis≤5×ULN;

    入选标准第 12 条

    Kidney function: Blood creatinine (Cr) ≤1.5×ULN or Cockcroft Gault formula ≥ 60 mL/min;

    入选标准第 13 条

  7. At least 1 measurable lesion as determined by RECIST 1.1;

    入选标准第 4 条

  8. A history of active immune deficiency or autoimmune diseases, including HIV positive, or others acquired or congenital immune deficiency diseases, or organ transplantation;

    排除标准第 13 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06492317,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age: more than 18 years, gender is not limited;
  2. Confirmed locally advanced or distant metastasis gastric or gastroesophageal junction adenocarcinoma that is inoperable by pathological examination;
  3. Confirmed HER2 2+or 3+ by immunohistochemistry (IHC);
  4. At least 1 measurable lesion as determined by RECIST 1.1;
  5. There is no prior systematic treatment, or the patient has received neoadjuvant/adjuvant chemotherapy, and the disease progresses or relapses more than 6 months after the treatment;
  6. Eastern Cooperative Oncology Group (ECOG)performance status of 0-1;
  7. Adequate organ function:
  8. Bone marrow function: Hemoglobin count (HGB)≥80g/L;
  9. Neutrophil count (NE)≥1.5×109/L;
  10. White blood cell count (WBC)≥3.5×109/L;
  11. Platelet count (PLT)≥100×109/L;
  12. Liver function: i. Serum total bilirubin (TBIL)≤1.5×ULN; ii. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP)≤3×ULN, patients with liver metastasis≤5×ULN;
  13. Kidney function: Blood creatinine (Cr) ≤1.5×ULN or Cockcroft Gault formula ≥ 60 mL/min;
  14. Cardiac function: New York Heart Association (NYHA) classification<Grade 3; Left ventricular ejection fraction≥50%;
  15. At least 3 months life expectancy ;
  16. The female of childbearing age must have taken reliable contraceptive measures or conducted a negative pregnancy test (serum or urine) within 7 days before enrollment, and are willing to use appropriate methods of contraception during the trial period and 8 weeks after the last administration of the test drug; the male must agree to use appropriate methods of contraception during the trial and 8 weeks after the last administration of the trial;
  17. Willing to join the study and signed an informed consent form (ICF) with good compliance and cooperation in follow-up.

排除标准:Exclusion Criteria:

  1. Allergy to any trial drug and its excipients, or serious allergy history, or contraindication of the trial drugs;
  2. Uncontrollable cardiovascular and cerebrovascular events , such as:
  3. NYHA grade 2 or above heart failure;
  4. Unstable angina pectoris;
  5. Myocardial infarction occurred within 12 months;
  6. Supraventricular or ventricular arrhythmia with clinical significance needs treatment or intervention;
  7. Cerebral hemorrhage and cerebral infarction (except for lacunar cerebral infarction without symptoms and without treatment);
  8. Serious cardiovascular and cerebrovascular events occurred within 12 months; Uncontrolled hypertension, i.e. systolic blood pressure>140 mmHg or diastolic blood pressure>90 mmHg after treatment;
  9. A history of arterial thrombosis or deep vein thrombosis within 6 months , or with evidence of bleeding tendency or medical history within 2 months, regardless of the severity;
  10. Stroke event or transient ischemic attack occurred within 12 months.
  11. Received systematic treatment with Chinese patent medicine or immunomodulatory drugs (including thymosin, interferon, interleukin, except for local use for ascites control) before the first administration within 2 weeks;
  12. A history of interstitial lung disease, non-infectious pneumonia, pulmonary fibrosis, acute lung disease, or systemic disease with poor control (including but not limited to diabetes, hypertension, etc.);
  13. A history of active immune deficiency or autoimmune diseases, including HIV positive, or others acquired or congenital immune deficiency diseases, or organ transplantation;
  14. Severe chronic or active infection requires systemic antibacterial, antifungal or antiviral treatment, including tuberculosis infection. A history of active tuberculosis infection ≥ 1 year should also be excluded, unless proved has been completed appropriate treatment;
  15. Brain metastasis or leptomeningeal metastasis;
  16. Clinically significant pleural effusion, pericardial effusion or ascites should be drained for many times within 2 weeks before the first administration of the drugs;
  17. Another clinically detectable primary malignant tumor at the time of recruitment, or other malignant tumors in the past 5 years (except for fully treated skin basal cell carcinoma or cervical carcinoma in situ);
  18. Any major surgery was performed ≤ 28 days before the drugs administration;
  19. History of allogeneic stem cell transplantation or organ transplantation;
  20. Be suffering gastrointestinal diseases: uodenal ulcer, ulcerative colitis, intestinal obstruction and others at present; or other conditions that may cause gastrointestinal bleeding or perforation judged by the researchers; or history of intestinal perforation or fistula, but has not recovered after surgical treatment;
  21. Live vaccine are inoculated within 4 weeks (inclusive) before the first administration of the drugs, not including seasonal influenza vaccines but intranasal vaccine;
  22. Other factors may lead to the forced termination of this trial according to the judgment of the investigator, such as other serious diseases (including psychological and mental diseases) requiring combined treatment, serious laboratory examination abnormalities, and family or social factors, which may affect the safety of the subject, or the collection of data and samples;
  23. Participating in other therapeutic clinical studies or using research instruments within 4 weeks before the first administration;
  24. Others conditions do not meet the inclusion according to the judgment of the investigator.

引自 ClinicalTrials.gov, NCT06492317, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06492317,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06492317